Please enable Javascript
David F. McDermott, MD
Articles by David F. McDermott, MD
Refractory RCC: Third-Line Treatment Considerations
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
View More
Improving Outcomes in Patients With Chromophobe, Papillary RCC
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
View More
Personalized RCC Care: Decreasing Overtreatment, Identifying Cured Patients in the Adjuvant Setting
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
View More
Considerations for Managing Patients on Maintenance RCC Therapy
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
View More
CheckMate 67T: Do Recent Updates Make This Practice-Changing?
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
View More
RCC Treatment Sequencing and Combination Approaches: JAVELIN Renal 101 and COSMIC-313
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
View More
What’s on the Horizon for RCC Treatment and Care?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
View More
RCC Highlights From ASCO GU: Adjuvant Treatment, Immunotherapy, Toxicities, and More
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
View More
Longer-Term Follow-Up on Frontline IO and TKI Studies and Impacts to Treatment Selection
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
View More
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
View More
ASCO GU Data Updates in Frontline Kidney Cancer: Was Anything Practice Changing?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
View More
RCC Panel Shares What They Are Most Excited About in the Field
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
View More
Phase 2 TIDE-A Study: Thoughts and Potential Treatment Impacts
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
View More
RCC Panel Reacts to LITESPARK-005 Data Presented at ESMO 2023
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
View More
Focus on Non-Clear Cell RCC: Frontline Treatment Options, Research Limitations, and More
Brian Rini, MD, FASCO
Roundtable
|
December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
View More
Panel Discusses the Value of Immunotherapy in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
View More
ESMO 2023: RENOTORCH Assesses Toripalimab and Axitinib in RCC
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
View More
Frontline Clear Cell Kidney Cancer: Treatment Selection and Patient Considerations
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
View More
Dr. David McDermott Shares His Favorite Uromigos Guests and Episodes
David F. McDermott, MD
Uromigos Live 2023
|
November 6, 2023
Dr. David McDermott from Beth Israel Deaconess Medical Center discusses his favorite Uromigos guests and episodes.
View More